Selected research
Industry Research
Paclitaxel and Docetaxel Industry Research Report 2026
Market perspective
The global Paclitaxel and Docetaxel market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Paclitaxel and Docetaxel is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Paclitaxel and Docetaxel is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Paclitaxel and Docetaxel is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Paclitaxel and Docetaxel include Yunnan Hande, Southpharma, Hainan Yew Pharm, TAPI (Teva), ScinoPharm, Samyang, Polymed, Phyton and Novasep, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Paclitaxel and Docetaxel market in terms of revenue (US$ million) and, where applicable, sales volume (K Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Paclitaxel and Docetaxel Market by Company
Yunnan Hande
Southpharma
Hainan Yew Pharm
TAPI (Teva)
ScinoPharm
Samyang
Polymed
Phyton
Novasep
Jiangsu Yew Biotechnology
Huiang biopharma
Fresenius-kabi
Paclitaxel and Docetaxel Segment by Type
Paclitaxel
Docetaxel
Paclitaxel and Docetaxel Segment by Application
Cervical Cancer
Ovarian Cancer
Breast Cancer
Others
Paclitaxel and Docetaxel Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Paclitaxel and Docetaxel market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Paclitaxel and Docetaxel and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Paclitaxel and Docetaxel.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Paclitaxel and Docetaxel manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Paclitaxel and Docetaxel by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Paclitaxel and Docetaxel in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Paclitaxel
- Docetaxel
Applications
- Cervical Cancer
- Ovarian Cancer
- Breast Cancer
- Others
Companies covered
- Yunnan Hande
- Southpharma
- Hainan Yew Pharm
- TAPI (Teva)
- ScinoPharm
- Samyang
- Polymed
- Phyton
- Novasep
- Jiangsu Yew Biotechnology
- Huiang biopharma
- Fresenius-kabi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Paclitaxel and Docetaxel Market Size (2021-2032)
- 2.2.2 Global Paclitaxel and Docetaxel Sales (2021-2032)
- 2.2.3 Global Paclitaxel and Docetaxel Market Average Price (2021-2032)
- 2.3 Paclitaxel and Docetaxel by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Paclitaxel
- 2.3.3 Docetaxel
- 2.4 Paclitaxel and Docetaxel by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cervical Cancer
- 2.4.3 Ovarian Cancer
- 2.4.4 Breast Cancer
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Paclitaxel and Docetaxel Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Paclitaxel and Docetaxel Sales (K Tons) of Manufacturers (2021-2026)
- 3.3 Global Paclitaxel and Docetaxel Revenue of Manufacturers (2021-2026)
- 3.4 Global Paclitaxel and Docetaxel Average Price by Manufacturers (2021-2026)
- 3.5 Global Paclitaxel and Docetaxel Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Paclitaxel and Docetaxel, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Paclitaxel and Docetaxel, Product Type & Application
- 3.8 Global Manufacturers of Paclitaxel and Docetaxel, Established Date
- 3.9 Global Paclitaxel and Docetaxel Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yunnan Hande
- 4.1.1 Yunnan Hande Company Information
- 4.1.2 Yunnan Hande Business Overview
- 4.1.3 Yunnan Hande Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yunnan Hande Paclitaxel and Docetaxel Product Portfolio
- 4.1.5 Yunnan Hande Recent Developments
- 4.2 Southpharma
- 4.2.1 Southpharma Company Information
- 4.2.2 Southpharma Business Overview
- 4.2.3 Southpharma Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Southpharma Paclitaxel and Docetaxel Product Portfolio
- 4.2.5 Southpharma Recent Developments
- 4.3 Hainan Yew Pharm
- 4.3.1 Hainan Yew Pharm Company Information
- 4.3.2 Hainan Yew Pharm Business Overview
- 4.3.3 Hainan Yew Pharm Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hainan Yew Pharm Paclitaxel and Docetaxel Product Portfolio
- 4.3.5 Hainan Yew Pharm Recent Developments
- 4.4 TAPI (Teva)
- 4.4.1 TAPI (Teva) Company Information
- 4.4.2 TAPI (Teva) Business Overview
- 4.4.3 TAPI (Teva) Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 TAPI (Teva) Paclitaxel and Docetaxel Product Portfolio
- 4.4.5 TAPI (Teva) Recent Developments
- 4.5 ScinoPharm
- 4.5.1 ScinoPharm Company Information
- 4.5.2 ScinoPharm Business Overview
- 4.5.3 ScinoPharm Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 ScinoPharm Paclitaxel and Docetaxel Product Portfolio
- 4.5.5 ScinoPharm Recent Developments
- 4.6 Samyang
- 4.6.1 Samyang Company Information
- 4.6.2 Samyang Business Overview
- 4.6.3 Samyang Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Samyang Paclitaxel and Docetaxel Product Portfolio
- 4.6.5 Samyang Recent Developments
- 4.7 Polymed
- 4.7.1 Polymed Company Information
- 4.7.2 Polymed Business Overview
- 4.7.3 Polymed Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Polymed Paclitaxel and Docetaxel Product Portfolio
- 4.7.5 Polymed Recent Developments
- 4.8 Phyton
- 4.8.1 Phyton Company Information
- 4.8.2 Phyton Business Overview
- 4.8.3 Phyton Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Phyton Paclitaxel and Docetaxel Product Portfolio
- 4.8.5 Phyton Recent Developments
- 4.9 Novasep
- 4.9.1 Novasep Company Information
- 4.9.2 Novasep Business Overview
- 4.9.3 Novasep Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novasep Paclitaxel and Docetaxel Product Portfolio
- 4.9.5 Novasep Recent Developments
- 4.10 Jiangsu Yew Biotechnology
- 4.10.1 Jiangsu Yew Biotechnology Company Information
- 4.10.2 Jiangsu Yew Biotechnology Business Overview
- 4.10.3 Jiangsu Yew Biotechnology Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Jiangsu Yew Biotechnology Paclitaxel and Docetaxel Product Portfolio
- 4.10.5 Jiangsu Yew Biotechnology Recent Developments
- 4.11 Huiang biopharma
- 4.11.1 Huiang biopharma Company Information
- 4.11.2 Huiang biopharma Business Overview
- 4.11.3 Huiang biopharma Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Huiang biopharma Paclitaxel and Docetaxel Product Portfolio
- 4.11.5 Huiang biopharma Recent Developments
- 4.12 Fresenius-kabi
- 4.12.1 Fresenius-kabi Company Information
- 4.12.2 Fresenius-kabi Business Overview
- 4.12.3 Fresenius-kabi Paclitaxel and Docetaxel Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Fresenius-kabi Paclitaxel and Docetaxel Product Portfolio
- 4.12.5 Fresenius-kabi Recent Developments
5 Global Paclitaxel and Docetaxel Market Scenario by Region
- 5.1 Global Paclitaxel and Docetaxel Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Paclitaxel and Docetaxel Sales by Region: 2021-2032
- 5.2.1 Global Paclitaxel and Docetaxel Sales by Region: 2021-2026
- 5.2.2 Global Paclitaxel and Docetaxel Sales by Region: 2027-2032
- 5.3 Global Paclitaxel and Docetaxel Revenue by Region: 2021-2032
- 5.3.1 Global Paclitaxel and Docetaxel Revenue by Region: 2021-2026
- 5.3.2 Global Paclitaxel and Docetaxel Revenue by Region: 2027-2032
- 5.4 North America Paclitaxel and Docetaxel Market Facts & Figures by Country
- 5.4.1 North America Paclitaxel and Docetaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Paclitaxel and Docetaxel Sales by Country (2021-2032)
- 5.4.3 North America Paclitaxel and Docetaxel Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Paclitaxel and Docetaxel Market Facts & Figures by Country
- 5.5.1 Europe Paclitaxel and Docetaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Paclitaxel and Docetaxel Sales by Country (2021-2032)
- 5.5.3 Europe Paclitaxel and Docetaxel Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Paclitaxel and Docetaxel Market Facts & Figures by Country
- 5.6.1 Asia Pacific Paclitaxel and Docetaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Paclitaxel and Docetaxel Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Paclitaxel and Docetaxel Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Paclitaxel and Docetaxel Market Facts & Figures by Country
- 5.7.1 South America Paclitaxel and Docetaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Paclitaxel and Docetaxel Sales by Country (2021-2032)
- 5.7.3 South America Paclitaxel and Docetaxel Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Paclitaxel and Docetaxel Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Paclitaxel and Docetaxel Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Paclitaxel and Docetaxel Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Paclitaxel and Docetaxel Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Paclitaxel and Docetaxel Sales by Type (2021-2032)
- 6.1.1 Global Paclitaxel and Docetaxel Sales by Type (2021-2032) & (K Tons)
- 6.1.2 Global Paclitaxel and Docetaxel Sales Market Share by Type (2021-2032)
- 6.2 Global Paclitaxel and Docetaxel Revenue by Type (2021-2032)
- 6.2.1 Global Paclitaxel and Docetaxel Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Paclitaxel and Docetaxel Revenue Market Share by Type (2021-2032)
- 6.3 Global Paclitaxel and Docetaxel Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Paclitaxel and Docetaxel Sales by Application (2021-2032)
- 7.1.1 Global Paclitaxel and Docetaxel Sales by Application (2021-2032) & (K Tons)
- 7.1.2 Global Paclitaxel and Docetaxel Sales Market Share by Application (2021-2032)
- 7.2 Global Paclitaxel and Docetaxel Revenue by Application (2021-2032)
- 7.2.1 Global Paclitaxel and Docetaxel Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Paclitaxel and Docetaxel Revenue Market Share by Application (2021-2032)
- 7.3 Global Paclitaxel and Docetaxel Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Paclitaxel and Docetaxel Value Chain Analysis
- 8.1.1 Paclitaxel and Docetaxel Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Paclitaxel and Docetaxel Production Mode & Process
- 8.2 Paclitaxel and Docetaxel Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Paclitaxel and Docetaxel Distributors
- 8.2.3 Paclitaxel and Docetaxel Customers
9 Global Paclitaxel and Docetaxel Analyzing Market Dynamics
- 9.1 Paclitaxel and Docetaxel Industry Trends
- 9.2 Paclitaxel and Docetaxel Industry Drivers
- 9.3 Paclitaxel and Docetaxel Industry Opportunities and Challenges
- 9.4 Paclitaxel and Docetaxel Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst